Overview

A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension

Status:
Completed

Trial end date:
2017-03-17

Target enrollment:

Participant gender:

Summary

To evaluate the impact of escalating doses of IW-1973 on endothelial function [using EndoPAT to measure fingertip small vessel pulse volume], blood pressure (BP), and heart rate.

Phase:

Phase 2

Details

Lead Sponsor:

Cyclerion Therapeutics
Ironwood Pharmaceuticals, Inc.

Treatments:

Praliciguat